Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3068 |
Name | glioblastoma |
Definition | A malignant astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has_material_basis_in abnormally proliferating cells derives_from multiple cell types including astrocytes and oligondroctyes. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3075 DOID:3080 |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00054496 | Phase II | Erlotinib | Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT00301418 | Phase Ib/II | Erlotinib | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
NCT00492687 | Phase II | Carboplatin Temozolomide Tamoxifen | Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas | Unknown status | USA | 0 |
NCT00669669 | Phase Ib/II | O6-benzylguanine Carmustine + Filgrastim + Plerixafor + Temozolomide | Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas | Terminated | USA | 0 |
NCT00906516 | Phase II | 81C6 + Bevacizumab | Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT00968240 | Phase I | Bevacizumab | Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) | Completed | USA | 0 |
NCT00998010 | Phase II | Bortezomib + Temozolomide | Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Completed | USA | 0 |
NCT01052363 | Phase I | Bevacizumab + Fosbretabulin | OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas | Withdrawn | USA | 0 |
NCT01067469 | Phase II | Bevacizumab Bevacizumab + Lomustine | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | Completed | USA | 0 |
NCT01107522 | Phase I | Carboxyamidotriazole Orotate + Temozolomide Carboxyamidotriazole Orotate | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | Active, not recruiting | USA | 0 |
NCT01112527 | Phase II | Dacomitinib | PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | Completed | USA | 0 |
NCT01130077 | Phase I | Poly ICLC | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas | Active, not recruiting | USA | 0 |
NCT01140568 | Phase II | Nilotinib | Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | Completed | USA | 0 |
NCT01149850 | Phase II | Bevacizumab + Temozolomide | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | Completed | USA | 0 |
NCT01177397 | Phase Ib/II | Onatasertib | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | Completed | USA | GBR | FRA | ESP | 0 |
NCT01238237 | Phase I | Cetuximab | Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma | Completed | USA | 0 |
NCT01260506 | Phase Ib/II | Bevacizumab + VB-111 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | Completed | USA | ISR | 0 |
NCT01266031 | Phase Ib/II | Bevacizumab + Vorinostat Bevacizumab | Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01269424 | Phase I | O6-benzylguanine + Temozolomide | O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma | Completed | USA | 0 |
NCT01269853 | Phase Ib/II | Bevacizumab | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | Recruiting | USA | 0 |
NCT01290263 | Phase Ib/II | Bevacizumab + Trebananib Trebananib | Amgen 386 for Recurrent Glioblastoma | Completed | USA | 0 |
NCT01331291 | Phase II | Bosutinib | Bosutinib in Adult Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01331616 | Phase I | Bevacizumab | Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab | Withdrawn | 0 | |
NCT01339039 | Phase I | Bevacizumab + Plerixafor | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Terminated | USA | 0 |
NCT01349660 | Phase Ib/II | Bevacizumab + Buparlisib | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | Completed | USA | 0 |
NCT01386710 | Phase Ib/II | Bevacizumab + Carboplatin | Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma | Suspended | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01430351 | Phase I | Metformin + Temozolomide Mefloquine + Temozolomide Memantine + Metformin + Temozolomide Mefloquine + Memantine + Temozolomide Mefloquine + Memantine + Metformin + Temozolomide Temozolomide Mefloquine + Metformin + Temozolomide Memantine + Temozolomide | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | Active, not recruiting | USA | 0 |
NCT01434602 | Phase Ib/II | Everolimus + Sorafenib | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Completed | USA | 0 |
NCT01435395 | Phase I | Bevacizumab + Bortezomib + Temozolomide | Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT01473901 | Phase I | Buparlisib + Temozolomide | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | Completed | USA | ESP | CAN | AUS | 0 |
NCT01478178 | Phase Ib/II | VAL-083 | Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor | Completed | USA | 0 |
NCT01478321 | Phase II | Bevacizumab + Temozolomide | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | Terminated | USA | 0 |
NCT01508117 | Phase II | Axitinib | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | Terminated | USA | 0 |
NCT01526837 | Phase I | Bevacizumab | Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence | Terminated | USA | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 0 |
NCT01591577 | Phase II | Lapatinib + Temozolomide | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | Completed | USA | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | DNK | CAN | 0 |
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01672463 | Phase I | OKN-007 | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients | Active, not recruiting | USA | 0 |
NCT01721577 | Phase Ib/II | AXL1717 | Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas | Terminated | USA | 0 |
NCT01730950 | Phase II | Bevacizumab | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01753713 | Phase II | Dovitinib | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT01756352 | Phase II | Bevacizumab | FET-PET for Evaluation of Response of Recurrent GBM to Avastin | Completed | USA | 0 |
NCT01788280 | Phase I | Bevacizumab | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | Withdrawn | USA | 0 |
NCT01790503 | Phase Ib/II | Pexidartinib Temozolomide | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT01800695 | Phase I | Temozolomide Depatuxizumab mafodotin | Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme | Completed | 0 | |
NCT01811498 | Phase Ib/II | Bevacizumab | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | Completed | USA | 0 |
NCT01814813 | Phase II | Bevacizumab | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | Terminated | USA | 0 |
NCT01837862 | Phase Ib/II | Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole | A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas | Completed | USA | 0 |
NCT01849146 | Phase I | Adavosertib + Temozolomide | WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme | Active, not recruiting | USA | 0 |
NCT01860638 | Phase III | Bevacizumab Lomustine | A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma | Completed | TUR | SWE | ROU | LVA | ITA | HRV | GRC | GBR | FRA | EST | ESP | CAN | BGR | AUT | 1 |
NCT01870726 | Phase Ib/II | Buparlisib + Capmatinib | Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma | Terminated | USA | NLD | ESP | DEU | CHE | 0 |
NCT01884740 | Phase Ib/II | Bevacizumab + Cetuximab | Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age | Terminated | USA | 0 |
NCT01891747 | Phase I | Bevacizumab + Temozolomide | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Completed | USA | 0 |
NCT01894061 | Phase II | Bevacizumab | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT01903330 | Phase II | Bevacizumab Cyclophosphamide Sargramostim | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT01904123 | Phase I | WP1066 | A Phase I Trial of WP1066 | Completed | USA | 0 |
NCT01925573 | Phase I | Bevacizumab | NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344) | Terminated | USA | 0 |
NCT01931098 | Phase II | Pazopanib + Topotecan | Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM) | Completed | USA | 0 |
NCT01933815 | Phase Ib/II | Bevacizumab TPI 287 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | Suspended | USA | 0 |
NCT01934361 | Phase Ib/II | Buparlisib + Lomustine Buparlisib + Carboplatin | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | Completed | USA | FRA | ESP | CAN | BEL | AUS | 0 |
NCT01954576 | Phase II | NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Terminated | USA | 0 | |
NCT01975701 | Phase II | Infigratinib | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | Completed | USA | NLD | ESP | CHE | BEL | AUS | 0 |
NCT01977677 | Phase Ib/II | Temozolomide Plerixafor | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT01986348 | Phase II | Selinexor | Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide | Terminated | USA | NLD | DNK | 0 |
NCT01989052 | Phase Ib/II | Lomustine Carboxyamidotriazole Orotate | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Terminated | USA | 0 |
NCT01999270 | Phase I | Bevacizumab + Irinotecan | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | Completed | USA | 0 |
NCT02010606 | Phase I | Bevacizumab Temozolomide | Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma | Completed | USA | 0 |
NCT02017717 | Phase III | Nivolumab Bevacizumab Ipilimumab + Nivolumab | A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143) | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUS | 0 |
NCT02026271 | Phase I | Ad-RTS-IL-12 plus AL | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | Completed | USA | 0 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02047214 | Phase II | Bevacizumab + Paclitaxel | Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | Terminated | USA | 0 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT02062827 | Phase I | M032 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1) | Active, not recruiting | USA | 0 |
NCT02067156 | Phase II | Mipsagargin | Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Completed | USA | 0 |
NCT02120287 | Phase II | Bevacizumab | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | Completed | USA | 0 |
NCT02133183 | Phase I | Sapanisertib | TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02137759 | Phase II | Vorinostat Temozolomide | MRSI to Predict Response to RT/TMZ and Vorinostat in GBM | Active, not recruiting | USA | 0 |
NCT02146066 | Expanded access | DCVax-L | Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 | Available | USA | 0 |
NCT02152982 | Phase II | Veliparib Temozolomide | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Active, not recruiting | USA | 1 |
NCT02157103 | Phase II | Bevacizumab | A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma | Completed | USA | 0 |
NCT02179086 | Phase II | Temozolomide | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | CAN | 0 |
NCT02197169 | Phase I | DNX-2401 DNX-2401 + Interferon gamma | DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) | Completed | USA | 0 |
NCT02238496 | Phase II | Perifosine + Temsirolimus | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Completed | USA | 0 |
NCT02285959 | Phase I | Bevacizumab | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | Recruiting | USA | 0 |
NCT02287428 | Phase I | NeoVax Pembrolizumab Temozolomide NeoVax + Pembrolizumab + Temozolomide NeoVax + Pembrolizumab | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM | Recruiting | USA | 0 |
NCT02311582 | Phase Ib/II | Pembrolizumab | MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas | Completed | USA | 0 |
NCT02311920 | Phase I | Temozolomide Nivolumab Ipilimumab | Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Completed | USA | 0 |
NCT02315534 | Phase Ib/II | Napabucasin Temozolomide | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | Completed | USA | CAN | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02331498 | Phase Ib/II | Pazopanib | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme (PAZOGLIO) | Recruiting | FRA | 0 |
NCT02336165 | Phase II | Durvalumab Bevacizumab + Durvalumab | Phase 2 Study of MEDI4736 in Patients With Glioblastoma | Completed | USA | AUS | 0 |
NCT02337491 | Phase II | Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab +/- Bevacizumab for Recurrent GBM | Completed | USA | 0 |
NCT02340156 | Phase II | SGT-53 Temozolomide | Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma | Terminated | USA | 1 |
NCT02342379 | Phase II | Bevacizumab + Evofosfamide | TH-302 in Combination With Bevacizumab for Glioblastoma | Completed | USA | 0 |
NCT02343406 | Phase II | Lomustine Depatuxizumab mafodotin Temozolomide | ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma | Completed | USA | POL | NLD | ITA | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 4 |
NCT02343549 | Phase II | Bevacizumab + Temozolomide | LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer | Terminated | USA | 0 |
NCT02345824 | Phase I | Ribociclib | Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma | Unknown status | USA | 0 |
NCT02348255 | Phase II | Bevacizumab + Carmustine | NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | Withdrawn | USA | 0 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02386826 | Phase I | Bevacizumab + Capmatinib | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | Completed | USA | 0 |
NCT02414165 | Phase II | Bevacizumab Lomustine Toca FC + Vocimagene amiretrorepvec Temozolomide | P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) | Terminated | USA | ISR | CAN | 1 |
NCT02423525 | Phase I | Afatinib | Safety Study of Afatinib for Brain Cancer | Completed | USA | 0 |
NCT02465268 | Phase II | pp65 Dendritic Cell Vaccine + Sargramostim | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II) | Completed | USA | 0 |
NCT02478164 | Phase II | Ponatinib | Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma | Completed | USA | 0 |
NCT02490800 | Phase Ib/II | BAL101553 | Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma | Completed | GBR | DEU | CHE | BEL | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02510950 | Phase I | Sargramostim Poly ICLC Temozolomide | Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |
NCT02511405 | Phase III | Bevacizumab VB-111 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) | Completed | USA | ISR | CAN | 0 |
NCT02521090 | Phase Ib/II | EGFRBi-armed autologous activated T cells | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma | Withdrawn | 0 | |
NCT02525692 | Phase II | ONC201 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Active, not recruiting | USA | 0 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02530502 | Phase Ib/II | Temozolomide Pembrolizumab | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |
NCT02573324 | Phase II | Temozolomide Depatuxizumab mafodotin + Temozolomide | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1) | Completed | USA | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT02586857 | Phase Ib/II | Acalabrutinib | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) | Active, not recruiting | USA | 0 |
NCT02605746 | Phase I | Ceritinib | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | Completed | USA | 0 |
NCT02607124 | Phase Ib/II | Ribociclib | Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02617589 | Phase III | Nivolumab Temozolomide | Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498) | Completed | USA | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 2 |
NCT02619864 | Phase Ib/II | Vistusertib | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | Completed | CAN | 0 |
NCT02626364 | Phase II | Crenolanib | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | Completed | USA | 0 |
NCT02648633 | Phase I | Nivolumab + Valproic acid | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02658981 | Phase I | Relatlimab Urelumab Nivolumab + Urelumab Nivolumab + Relatlimab | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | Completed | USA | 0 |
NCT02661282 | Phase Ib/II | Autologous CMV-specific CTLs + Temozolomide | Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | Completed | USA | 0 |
NCT02663271 | Phase II | Bevacizumab | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02667587 | Phase II | Temozolomide Nivolumab + Temozolomide | Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). | Completed | USA | SWE | POL | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 2 |
NCT02717962 | Phase II | VAL-083 | Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT02743078 | Phase II | Bevacizumab | Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | Terminated | USA | 0 |
NCT02754362 | Phase II | Poly ICLC Bevacizumab | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT02765165 | Phase Ib/II | Lomustine + USL311 USL311 | Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) | Terminated | USA | ESP | 0 |
NCT02766699 | Phase I | EGFR(V)-EDV-Dox | A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV) | Unknown status | USA | 0 |
NCT02768389 | Phase I | Bevacizumab | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | Completed | USA | 0 |
NCT02780024 | Phase II | Metformin | Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM | Active, not recruiting | CAN | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02798406 | Phase II | DNX-2401 + Pembrolizumab | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE) | Completed | USA | CAN | 0 |
NCT02800486 | Phase II | Cetuximab | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | Recruiting | USA | 0 |
NCT02829723 | Phase Ib/II | BLZ945 BLZ945 + Spartalizumab | Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Terminated | USA | ITA | ISR | ESP | CHE | 3 |
NCT02844439 | Phase II | Tesevatinib | Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT02852655 | Phase 0 | Pembrolizumab | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | Completed | USA | 0 |
NCT02858895 | Phase II | MDNA55 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT02861898 | Phase Ib/II | Cetuximab + Mannitol | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | Recruiting | USA | 0 |
NCT02866747 | Phase Ib/II | Durvalumab | A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI) | Active, not recruiting | FRA | 0 |
NCT02871843 | Phase I | RRx-001 + Temozolomide | Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) | Completed | USA | 0 |
NCT02876003 | Phase II | Mipsagargin | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | Withdrawn | USA | 0 |
NCT02885324 | Phase II | Cabozantinib | Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children | Terminated | USA | 0 |
NCT02928575 | Phase II | Sunitinib + Temozolomide | Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma | Unknown status | CAN | 0 |
NCT02942264 | Phase Ib/II | Zotiraciclib Temozolomide + Zotiraciclib | TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | Completed | USA | 0 |
NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
NCT02974621 | Phase II | Bevacizumab Cediranib + Olaparib | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT02977780 | Phase II | CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Recruiting | USA | 0 |
NCT02981940 | Phase II | Abemaciclib | A Study of Abemaciclib in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT03014804 | Phase II | DCVax-L DCVax-L + Nivolumab | Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT03018288 | Phase II | Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) | Terminated | USA | 0 |
NCT03027388 | Phase I | LB-100 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | Completed | USA | 0 |
NCT03047473 | Phase II | Avelumab | Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ) | Completed | CAN | 0 |
NCT03107780 | Phase I | KRT-232 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | Suspended | USA | 0 |
NCT03128047 | Phase I | Bevacizumab + Temozolomide | HUMC 1612: Optune NovoTTF-200A System | Active, not recruiting | USA | 0 |
NCT03139916 | Phase II | Bavituximab + Temozolomide | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03149003 | Phase II | Bevacizumab + DSP-7888 Bevacizumab | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G) | Completed | USA | CAN | 3 |
NCT03150862 | Phase Ib/II | Pamiparib Pamiparib + Temozolomide | A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma | Completed | USA | NLD | CHE | 0 |
NCT03174197 | Phase Ib/II | Atezolizumab + Temozolomide | Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT03197506 | Phase II | Pembrolizumab + Temozolomide Pembrolizumab | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | Active, not recruiting | USA | 0 |
NCT03212742 | Phase Ib/II | Olaparib + Temozolomide | Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients (OLA-TMZ-RTE-01) | Active, not recruiting | FRA | 0 |
NCT03216499 | Phase II | PT2385 | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT03223103 | Phase I | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | Active, not recruiting | USA | 0 | |
NCT03224104 | Phase I | Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) | Completed | NLD | FRA | DEU | CHE | AUT | 0 |
NCT03233152 | Phase I | Ipilimumab + Nivolumab | Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi) | Unknown status | BEL | 0 |
NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | ISR | AUS | 0 |
NCT03250299 | Phase I | BAL101553 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | Terminated | USA | 0 |
NCT03277638 | Phase Ib/II | Pembrolizumab | Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT03294486 | Phase Ib/II | Flucytosine + TG6002 | Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients (ONCOVIRAC) | Unknown status | FRA | 0 |
NCT03296696 | Phase I | AMG 596 | Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma | Terminated | USA | NLD | FRA | ESP | DEU | AUS | 0 |
NCT03332355 | Phase I | PAC-1 + Temozolomide | Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 | Terminated | USA | 0 |
NCT03341806 | Phase I | Avelumab | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | Completed | USA | 0 |
NCT03344250 | Phase I | EGFRBi-armed autologous activated T cells | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT03347617 | Phase II | Pembrolizumab | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03367715 | Phase II | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | Completed | USA | 0 |
NCT03382977 | Phase I | VBI-1901 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Recruiting | USA | 0 |
NCT03383978 | Phase I | Ezabenlimab + NK-92/5.28.z | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma (CAR2BRAIN) | Active, not recruiting | DEU | 0 |
NCT03405792 | Phase II | Pembrolizumab + Temozolomide | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) | Active, not recruiting | USA | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03422094 | Phase I | Ipilimumab + NeoVax + Nivolumab NeoVax + Nivolumab | Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Terminated | USA | 0 |
NCT03423628 | Phase I | AZD1390 | A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer | Recruiting | USA | GBR | 1 |
NCT03425292 | Phase I | Temozolomide Ipilimumab + Nivolumab Nivolumab | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | Completed | USA | 0 |
NCT03426891 | Phase I | Pembrolizumab + Temozolomide + Vorinostat | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Active, not recruiting | USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL | 2 |
NCT03452579 | Phase II | Bevacizumab + Nivolumab | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | Active, not recruiting | USA | 0 |
NCT03452930 | Phase I | Tinostamustine | Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma | Completed | USA | 0 |
NCT03463265 | Phase II | Lomustine + Nab-rapamycin Nab-rapamycin Nab-rapamycin + Temozolomide Bevacizumab + Nab-rapamycin | ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT03466450 | Phase Ib/II | Glasdegib + Temozolomide | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma (GEINOGLAS) | Completed | ESP | 0 |
NCT03491683 | Phase Ib/II | Cemiplimab + INO-5401 + INO-9012 + Temozolomide | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT03493932 | Phase I | Nivolumab + Relatlimab | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | Completed | USA | 0 |
NCT03514069 | Phase I | Ruxolitinib Ruxolitinib + Temozolomide | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03532295 | Phase II | Bevacizumab + Epacadostat + Radiotherapy + Retifanlimab Bevacizumab + Radiotherapy + Retifanlimab | INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | Active, not recruiting | USA | 0 |
NCT03535350 | Phase I | Ibrutinib Ibrutinib + Temozolomide | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT03581292 | Phase II | Temozolomide + Veliparib Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT03587038 | Phase I | OKN-007 + Temozolomide | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT03596086 | Phase Ib/II | HSV-Tk + Valacyclovir | HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM | Recruiting | USA | 0 |
NCT03603405 | Phase Ib/II | HSV-Tk | HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM | Recruiting | USA | 0 |
NCT03605550 | Phase I | Unesbulin | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | Active, not recruiting | USA | 0 |
NCT03607643 | Phase Ib/II | Temozolomide Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Cannabidiol + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bortezomib Bortezomib + Cannabidiol Cannabidiol + Gemcitabine Cannabidiol + Temozolomide Gemcitabine | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | Unknown status | USA | 0 |
NCT03631836 | Phase I | Andecaliximab + Bevacizumab | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01) | Unknown status | FRA | 0 |
NCT03636477 | Phase I | Ad-RTS-IL-12 plus AL + Nivolumab | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 | Completed | USA | 0 |
NCT03637764 | Phase Ib/II | Atezolizumab + Isatuximab Isatuximab | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | Terminated | USA | NLD | ITA | ESP | CZE | CAN | BEL | 1 |
NCT03643549 | Phase Ib/II | Bortezomib + Temozolomide | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17) (BORTEM-17) | Recruiting | NOR | 0 |
NCT03657576 | Phase I | C134-HSV-1 | Trial of C134 in Patients With Recurrent GBM (C134-HSV-1) | Active, not recruiting | USA | 0 |
NCT03661723 | Phase II | Bevacizumab Pembrolizumab Bevacizumab + Pembrolizumab | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | Completed | USA | 0 |
NCT03673787 | Phase Ib/II | Atezolizumab + Ipatasertib | A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) | Unknown status | GBR | 0 |
NCT03681028 | Phase I | Feasibility of Individualized Therapy for Recurrent GBM | Active, not recruiting | USA | 0 | |
NCT03688178 | Phase II | pp65 Dendritic Cell Vaccine + Temozolomide pp65 Dendritic Cell Vaccine + Temozolomide + Varlilumab | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe) | Active, not recruiting | USA | 0 |
NCT03696355 | Phase I | GDC-0084 | Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas | Completed | USA | 0 |
NCT03707457 | Phase I | Ipilimumab + Nivolumab MK-4166 + Nivolumab Epacadostat + Nivolumab | Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | Terminated | USA | 0 |
NCT03714334 | Phase I | DNX-2440 | DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma | Terminated | ESP | 0 |
NCT03726515 | Phase I | CART-EGFRvIII + Pembrolizumab | CART-EGFRvIII + Pembrolizumab in GBM | Completed | USA | 0 |
NCT03732352 | Phase II | Osimertinib | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma | Completed | USA | 0 |
NCT03743662 | Phase II | Nivolumab Bevacizumab | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT03749187 | Phase I | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) | Recruiting | USA | 0 |
NCT03750071 | Phase Ib/II | Avelumab + VXM01 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | Unknown status | DEU | 0 |
NCT03776071 | Phase III | Enzastaurin Temozolomide Enzastaurin + Temozolomide | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | Completed | USA | CAN | 1 |
NCT03782415 | Phase Ib/II | Temozolomide Ibudilast + Temozolomide | Study to Evaluate Ibudilast and TMZ Combo Treatment in Recurrent GBM | Active, not recruiting | USA | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT03856099 | Phase II | Tanibirumab | TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab | Terminated | USA | AUS | 0 |
NCT03893487 | Phase I | CUDC-907 | Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) | Active, not recruiting | USA | CHE | 0 |
NCT03896568 | Phase I | DNX-2401 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Recruiting | USA | 0 |
NCT03911388 | Phase I | HSV-1 G207 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Active, not recruiting | USA | 0 |
NCT03919071 | Phase II | Dabrafenib + Trametinib | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | Recruiting | USA | 1 |
NCT03961971 | Phase I | Sabatolimab + Spartalizumab | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | Active, not recruiting | USA | 0 |
NCT03965494 | Phase I | Bemcentinib | AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | Terminated | USA | 0 |
NCT03970447 | Phase II | Lomustine Regorafenib Temozolomide | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | DEU | CHE | CAN | AUS | 0 |
NCT03975829 | FDA approved | Dabrafenib + Trametinib | Pediatric Long-Term Follow-up and Rollover Study | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT03995706 | Phase I | Sacituzumab govitecan-hziy | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | Completed | USA | 0 |
NCT04003649 | Phase I | Anti-IL13RA2 CAR-T cells Anti-IL13RA2 CAR-T cells + Ipilimumab + Nivolumab Anti-IL13RA2 CAR-T cells + Nivolumab | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | Recruiting | USA | 0 |
NCT04013672 | Phase II | Montanide ISA 51 + Pembrolizumab + Sargramostim + SurVaxM | Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence | Completed | USA | 0 |
NCT04015700 | Phase I | GNOS-PV01 + INO-9012 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT04047303 | Phase I | CC-90010 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma | Terminated | USA | ESP | 0 |
NCT04049669 | Phase II | Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Recruiting | USA | 0 |
NCT04051606 | Phase II | Regorafenib | Phase II Study of Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04074785 | Phase I | Abemaciclib + Bevacizumab | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | Active, not recruiting | USA | 0 |
NCT04089449 | Phase I | PRT811 | A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis | Completed | USA | 0 |
NCT04116658 | Phase Ib/II | EO2401 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma (ROSALIE) | Completed | USA | FRA | ESP | DEU | 0 |
NCT04118036 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib + Pembrolizumab In Glioblastoma | Withdrawn | USA | 0 |
NCT04121455 | Phase Ib/II | NOX-A12 Bevacizumab + NOX-A12 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients (GLORIA) | Active, not recruiting | DEU | 0 |
NCT04145115 | Phase II | Ipilimumab + Nivolumab | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | Suspended | USA | 1 |
NCT04195139 | Phase II | Nivolumab + Temozolomide Temozolomide | Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM (NUTMEG) | Active, not recruiting | USA | AUS | 0 |
NCT04197934 | Phase I | WSD0922 | WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases | Recruiting | USA | 0 |
NCT04201873 | Phase I | DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Pembrolizumab + Poly ICLC | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04214392 | Phase I | Chlorotoxin-CD28-CD3z-CD19t CART cells | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |
NCT04216329 | Phase I | Selinexor + Temozolomide | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | USA | 0 |
NCT04221503 | Phase II | Niraparib | Niraparib/TTFields in GBM | Active, not recruiting | USA | 0 |
NCT04225039 | Phase II | INCAGN01876 + Retifanlimab | Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04254419 | Phase I | Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas | Not yet recruiting | USA | 0 | |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Completed | USA | GBR | ESP | DEU | 1 |
NCT04280848 | Phase Ib/II | UCPVax | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma (UCPVax-Glio) | Active, not recruiting | FRA | 0 |
NCT04295759 | Phase I | INCB7839 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | Active, not recruiting | USA | 0 |
NCT04324840 | Phase Ib/II | CC-90010 + Temozolomide | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Subjects With Newly Diagnosed Glioblastoma | Terminated | USA | SWE | NOR | NLD | ITA | ESP | DNK | 0 |
NCT04373785 | Phase Ib/II | NG101m + Temozolomide | NG101m Adjuvant Therapy in Glioblastoma Patients | Not yet recruiting | USA | 0 |
NCT04388475 | Phase II | OKN-007 + Temozolomide | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT04406272 | Phase II | Bevacizumab + VB-111 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | Terminated | USA | 0 |
NCT04421378 | Phase Ib/II | Lomustine + Selinexor Lomustine Selinexor + Temozolomide Temozolomide Selinexor | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Terminated | USA | CAN | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT04443010 | Phase Ib/II | Temozolomide Onfekafusp alfa + Temozolomide | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma (GLIOSUN) | Recruiting | CHE | 0 |
NCT04444427 | Phase Ib/II | GLR2007 | Evaluation of GLR2007 for Advanced Solid Tumors | Completed | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04479241 | Phase I | Pembrolizumab + PVSRIPO | A Phase 1 Study of PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma | Completed | USA | 0 |
NCT04482933 | Phase II | HSV-1 G207 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Recruiting | USA | 0 |
NCT04485949 | Phase II | Temozolomide IGV-001 + Temozolomide | A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma - the ImmuneSense Study | Active, not recruiting | USA | 0 |
NCT04555577 | Phase I | Peposertib Temozolomide | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04573192 | Phase Ib/II | Lomustine + Onfekafusp alfa Lomustine | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR) | Recruiting | ITA | FRA | DEU | CHE | 0 |
NCT04590664 | Phase Ib/II | Verteporfin | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | Recruiting | USA | 0 |
NCT04599647 | Expanded access | PVSRIPO | EAP for the Treatment of Glioblastoma With PVSRIPO | No longer available | USA | 0 |
NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
NCT04608812 | Phase I | OS2966 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | Terminated | USA | 0 |
NCT04614909 | Phase I | Olaparib Pamiparib Pamiparib + Temozolomide Olaparib + Pamiparib + Temozolomide | Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM | Recruiting | USA | 0 |
NCT04629209 | Phase II | ONC201 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Withdrawn | USA | 0 |
NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | Recruiting | USA | DEU | CAN | AUS | 0 |
NCT04656535 | Phase I | Zimberelimab AB154 AB154 + Zimberelimab | AB154 Combined With AB122 for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04681677 | Phase II | Bevacizumab | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (IORT) | Terminated | USA | 0 |
NCT04691960 | Phase II | Metformin | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | Recruiting | USA | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Completed | USA | ITA | GBR | FRA | BEL | 3 |
NCT04729959 | Phase II | Atezolizumab + Tocilizumab | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04741984 | Phase I | MT-201-GBM | Monocyte Antigen Carrier Cells for Newly Diagnosed GBM | Withdrawn | 0 | |
NCT04752813 | Phase II | BPM 31510 + Temozolomide | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | Recruiting | USA | 0 |
NCT04765098 | Phase II | Tamoxifen Lomustine | Tamoxifen Versus Lomustine After First Recurrence in GBM Patients | Recruiting | CAN | 0 |
NCT04809805 | Phase I | BAY2666605 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Terminated | USA | 0 |
NCT04817254 | Phase II | Ipilimumab + Nivolumab + Temozolomide | Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT04826393 | Phase I | ASP8374 + Cemiplimab | ASP8374 + Cemiplimab in Recurrent Glioma | Active, not recruiting | USA | 0 |
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04854044 | Phase I | ONC201 | ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT04874506 | Phase II | Tempol | MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | Unknown status | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Active, not recruiting | USA | 0 |
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | NLD | ITA | CHE | 0 |
NCT04922723 | Phase Ib/II | Daratumumab | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma (PRIDE) | Recruiting | USA | 0 |
NCT04977375 | Phase Ib/II | Pembrolizumab | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Recruiting | USA | CAN | 0 |
NCT04982926 | Phase I | TAS2940 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Active, not recruiting | USA | FRA | 0 |
NCT05039281 | Phase Ib/II | Atezolizumab + Cabozantinib | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05052957 | Phase II | Carmustine + Filgrastim + O6-benzylguanine + Temozolomide | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) | Recruiting | USA | 0 |
NCT05053880 | Phase Ib/II | ACT001 + Pembrolizumab ACT001 | A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme | Unknown status | USA | 0 |
NCT05074992 | Phase II | Ipilimumab | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma (NeAT Glio) | Terminated | GBR | 0 |
NCT05076513 | Phase I | Niraparib | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | Recruiting | USA | 0 |
NCT05083754 | Phase I | Retifanlimab Temozolomide Retifanlimab + Temozolomide | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | Recruiting | USA | 0 |
NCT05084430 | Phase Ib/II | M032 + Pembrolizumab | Study of Pembrolizumab and M032 (NSC 733972) | Recruiting | USA | 0 |
NCT05095441 | Phase I | MVR-C5252 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | Not yet recruiting | USA | 0 |
NCT05096481 | Phase II | PEP-CMV + Temozolomide | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Recruiting | USA | 0 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | NZL | CAN | AUS | 0 |
NCT05106296 | Phase I | Cyclophosphamide + Etoposide + Ibrutinib + Indoximod | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | Recruiting | USA | 0 |
NCT05120960 | Phase I | Tepotinib Osimertinib + Tepotinib | A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors | Withdrawn | 0 | |
NCT05163080 | Phase II | SurVaxM + Temozolomide Montanide ISA 51 + Sargramostim + SurVaxM + Temozolomide | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE) | Active, not recruiting | USA | 0 |
NCT05182905 | Phase I | AZD1390 | Phase 0 Plus Expansion Study of AZD1390 in Recurrent GBM Patients | Recruiting | USA | 0 |
NCT05183204 | Phase II | GDC-0084 + Metformin | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | Recruiting | USA | 0 |
NCT05187624 | Phase I | RO7428731 | A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma | Active, not recruiting | USA | NLD | ESP | DNK | CAN | AUS | 0 |
NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |
NCT05235737 | FDA approved | Pembrolizumab | The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab (PIRG) | Recruiting | POL | 0 |
NCT05256290 | Phase I | BDTX-1535 BDTX-1535 + Temozolomide | Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations | Recruiting | USA | 0 |
NCT05271240 | Phase III | Bevacizumab + Temozolomide Temozolomide | Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | Recruiting | USA | 0 |
NCT05283109 | Phase I | P30-EPS + Poly ICLC | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) | Recruiting | USA | 0 |
NCT05284643 | Phase 0 | Bevacizumab | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05297864 | Phase II | Niraparib | PARP Inhibition for Gliomas (PI-4G or pi4g) | Terminated | USA | 0 |
NCT05324501 | Phase I | MTX110 Lomustine + MTX110 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma (MAGIC-G1) | Active, not recruiting | USA | 0 |
NCT05326464 | Phase III | Tofacitinib | Tofacitinib in Recurrent GBM Patients | Recruiting | USA | 0 |
NCT05353530 | Phase I | Autologous CXCR2-modified CD70 CAR-T cells | Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT) | Recruiting | USA | 0 |
NCT05366179 | Phase I | CAR.B7-H3T cells | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | Recruiting | USA | 0 |
NCT05376800 | Phase I | BI 907828 | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | Recruiting | USA | ESP | BEL | 0 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |
NCT05410301 | Phase 0 | Bevacizumab + Lomustine | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT05423210 | Phase I | Atezolizumab | Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme | Recruiting | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Active, not recruiting | ESP | CHE | 0 |
NCT05432804 | Phase Ib/II | Selinexor + Temozolomide Temozolomide | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Recruiting | USA | 0 |
NCT05450744 | Phase I | 131I-TLX-101 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (IPAX-2) | Recruiting | NZL | NLD | AUT | AUS | 0 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Recruiting | USA | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05503797 | Phase II | Cobicistat + PLX8394 PLX8394 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Recruiting | USA | SWE | ITA | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05557292 | Phase I | RMC-5552 | RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05561374 | Phase I | OKN-007 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 0 |
NCT05599984 | Phase I | ABBV-706 ABBV-706 + Budigalimab ABBV-706 + Cisplatin ABBV-706 + Carboplatin | Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | ESP | DEU | AUS | 2 |
NCT05627323 | Phase I | CHM-1101 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Active, not recruiting | USA | 0 |
NCT05635734 | Phase Ib/II | Azeliragon | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | Active, not recruiting | ESP | 0 |
NCT05660369 | Phase I | CARv3-TEAM-E T-cells | CARv3-TEAM-E T Cells in Glioblastoma | Recruiting | USA | 0 |
NCT05685004 | Phase II | Temozolomide Temozolomide + TVI-Brain-1 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | Recruiting | USA | 0 |
NCT05686798 | Phase I | Ad5-yCD/mutTK(SR39)rep-ADP | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | Recruiting | USA | 0 |
NCT05698199 | Phase I | ITI-1001 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |
NCT05698524 | Phase I | Abexinostat + Temozolomide | A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma | Recruiting | USA | 0 |
NCT05700955 | Phase I | Pembrolizumab + Temozolomide | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05743595 | Phase I | Personalized cancer vaccine + Retifanlimab | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Recruiting | USA | 0 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05798507 | Phase I | RO5126766 Defactinib | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Recruiting | USA | 0 |
NCT05879120 | Phase II | Pembrolizumab | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Withdrawn | USA | 0 |
NCT05887882 | Phase I | TGF-beta-imprinted NK cells | Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Brain Tumors (PNOC028) | Recruiting | USA | 0 |
NCT05909618 | Phase II | Crizanlizumab + Nivolumab Crizanlizumab | Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases (14) | Recruiting | ISR | 0 |
NCT05929495 | Phase II | Metformin + Temozolomide Metformin | Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma | Not yet recruiting | ITA | 0 |
NCT05938387 | Phase I | CVGBM | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | Recruiting | NLD | DEU | BEL | 0 |
NCT05956821 | Phase Ib/II | Bevacizumab + Cetuximab | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | Recruiting | USA | 0 |
NCT05977322 | Phase I | 177Lu-FF58 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | NLD | ITA | ISR | ESP | CHE | 0 |
NCT06011109 | Phase Ib/II | Bevacizumab APG-157 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | Recruiting | USA | 0 |
NCT06058988 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | Recruiting | USA | 0 |
NCT06061809 | Phase II | Bevacizumab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |
NCT06126744 | Phase I | MVR-C5252 | Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252 (PuMP) | Recruiting | USA | 0 |
NCT06157541 | Phase Ib/II | CYT-101 + Pembrolizumab | T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP) | Recruiting | AUS | 0 |
NCT06160206 | Phase II | Bevacizumab + Retifanlimab Bevacizumab | Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | Not yet recruiting | USA | 0 |
NCT06186401 | Phase I | E-SYNC T cells Cyclophosphamide + Fludarabine | Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells | Recruiting | USA | 0 |
NCT06193174 | Phase I | C134-HSV-1 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | Not yet recruiting | USA | 0 |
NCT06264388 | Phase II | Toca FC + Vocimagene amiretrorepvec | DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | Recruiting | USA | 0 |
NCT06297512 | Phase II | Doxorubicin + Temozolomide | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | Recruiting | ITA | 0 |
NCT06325683 | Phase II | Nivolumab + Relatlimab Lomustine | Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT06333899 | Phase I | Lorlatinib Cisplatin + Cyclophosphamide + Lorlatinib + Vincristine Sulfate Carboplatin + Cyclophosphamide + Etoposide + Lorlatinib + Methotrexate + Vincristine Sulfate | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | Not yet recruiting | USA | NLD | DEU | CAN | AUS | 0 |
NCT06336291 | Phase II | Lomustine + Onfekafusp alfa | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (GLIOSTELLA) | Not yet recruiting | USA | 0 |
NCT06388733 | Phase III | Niraparib Temozolomide | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | Recruiting | USA | 0 |
NCT06413706 | Phase II | Abemaciclib + Temozolomide Temozolomide | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Not yet recruiting | USA | ROU | ITA | FRA | ESP | DNK | BEL | 1 |
NCT06455605 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | Not yet recruiting | USA | 0 |
NCT06463184 | Phase I | Xevinapant | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) | Recruiting | USA | 0 |
NCT06501911 | Phase I | Bicalutamide | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma | Not yet recruiting | USA | 0 |
NCT06504381 | Phase Ib/II | Toca FC + Vocimagene amiretrorepvec Temozolomide + Toca FC + Vocimagene amiretrorepvec | DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Not yet recruiting | USA | 0 |
NCT06521567 | Phase Ib/II | Cobolimab + Dostarlimab-gxly | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DNK | DEU | CZE | BRA | ARG | 1 |
NCT06556563 | Phase III | Pembrolizumab + Temozolomide | EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (EF-41) | Recruiting | USA | 0 |
NCT06614855 | Phase I | C134-HSV-1 | A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma | Not yet recruiting | USA | 0 |
NCT06630260 | Phase Ib/II | Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) | Recruiting | GBR | 0 |
NCT06632236 | Phase I | Amivantamab-vmjw | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) | Recruiting | GBR | 0 |
NCT06639607 | Phase Ib/II | Nivolumab + PEP-CMV + Temozolomide | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) | Not yet recruiting | USA | 0 |